The state of Michigan currently has 24 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
Parkinson's Disease Progression Study
Recruiting
Disease Progression Study
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/18/2024
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
06/13/2024
Locations: Pd0060 50110, Ann Arbor, Michigan +3 locations
Conditions: Parkinson Disease
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Recruiting
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/07/2024
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
06/04/2024
Locations: University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center, Ann Arbor, Michigan +2 locations
Conditions: Parkinson's Disease
STEM-Parkinson's Disease
Recruiting
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/04/2024
Locations: Quest Research, Farmington Hills, Michigan +1 locations
Conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism
AMX0035 and Progressive Supranuclear Palsy
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/31/2024
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
05/29/2024
Locations: Quest Research Institute, LLC, Farmington Hills, Michigan
Conditions: Parkinson's Disease
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/29/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Vestibulopathy as a Cause of Imbalance in Parkinson
Recruiting
Balance problems and falls are common in people with Parkinson's disease but respond poorly to dopamine stimulating medications suggesting other causes. The main goal of this study is to assess whether imbalance and gait problems in people with Parkinson's disease may be related to vestibular (inner ear balance center) changes not related to loss of dopamine in the brain.
Gender:
All
Ages:
45 years and above
Trial Updated:
04/22/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan +1 locations
Conditions: Parkinson's Disease
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
04/17/2024
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
Rostock International Parkinson's Disease Study (ROPAD)
Recruiting
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
03/21/2024
Locations: Michigan Institute for Neurological Disorders, Farmington Hills, Michigan
Conditions: Parkinson´s Disease
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Recruiting
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in u... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/08/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan
Conditions: Parkinson's Disease Psychosis